billion, respectively, from the human health segment of Organon
BioSciences (OBS), which was acquired on November 19, 2007.
b/ Animal Health Net sales for the three and nine months ended September
30, 2008 include net sales of $503 million and $1.5 billion, respectively,
from the animal health segment of OBS, which was acquired on November 19,
2007.
c/ Products acquired in OBS acquisition on November 19, 2007.
NOTE: Additional information about U.S. and international sales for
specific products is available by calling the company or visiting the
Investor Relations Web site at http://ir.schering-plough.com.
SCHERING-PLOUGH CORPORATION
Reconciliation of Non-U.S. GAAP Financial Measures
Adjusted net sales, defined as Net sales plus an assumed 50 percent of
global cholesterol joint venture net sales.
(Dollars in millions) Three months ended September 30,
(unaudited)
--------------------------------
2008 2007 %
--------------------------------
Net sales, as reported a/ $4,576 $2,812 63%
50 percent of cholesterol joint
venture net sales b/ 545 639 (15%)
Adjusted net sales b/ $5,121 $3,451 48%
(Dollars in millions) Nine months ended September 30,
(unaudited)
--------------------------------
2008 2007 %
--------------
'/>"/>
| SOURCE Schering-Plough Corporation Copyright©2008 PR Newswire. All rights reserved |